United States: December Is FDA's Month For Giving And Delaying

Last Updated: December 21 2015
Article by Michael A. Walsh

FDA capitulates, dropping a meritless enforcement action against Pacira and putting off Amarin until February 17, 2016.

Three years have passed since the Second Circuit paved new ground with the landmark decision in US v. Caronia. At the time, some commentators opined that the FDA enforcement world as the government knew it had ended and it was time to rethink how the FDA and industry could work in tandem to navigate the treacherous waters of regulating the speech of FDA regulated industry. Chief Justice Rehnquist foresaw this day in his dissenting opinion in Central Hudson, but all now agree it is time for industry and FDA to jointly fashion a regulatory regimen that anticipates due process, the First Amendment and limits arbitrary agency action. As Amarin and Pacira demonstrate, the FDA has finally come to peace with defeat and has placed among its "Front Burner Priorities" the task to "[r]e-evaluate our regulation of drug advertising and promotion in light of current jurisprudence around the 1st Amendment." There are plenty of good reasons for the FDA and industry to work together to solve the issue of who, what, where, when, why and how something less than two random control clinical trials can be relied on when disseminating information in the marketing of FDA regulated products.

In Amarin v. FDA, 1:15-CV-03588-PAE, Doc. 73 (SDNY Aug. 7, 2015). The Court built on Caronia and handed the FDA a complete defeat granting a preliminary injunction concerning enforcement for disseminating information not in the Food and Drug Administration (FDA) approved label (i.e. off-label). The court concluded that more, not less, truthful information was needed. The court in Amarin flatly rejected the position the FDA has been touting for decades— that it was not prosecuting speech but conduct that is evidence of intent. The court ruled that "the FDA may not bring such an action based on truthful promotional speech alone, consistent with the First Amendment." The court also rejected the government's attempt to rewrite the holding in Caronia:

"Where the speech at issue consists of truthful and non-misleading speech promoting the off-label use of an FDA-approved drug, such speech, under Caronia, cannot be the act upon which an action for misbranding is based."

After granting preliminary relief, the court ordered the parties to meet and file a report "as to the future course and next steps in the case." The deadline was originally August 28, 2015, a date that has been repeatedly moved to allow the parties to "continue to engage in settlement discussions." On December 16, 2015, the deadline was moved yet again, this time until February 17, 2016.

On Sept. 9, 2015, shortly after the FDA's shellacking in Amarin, the Southern District had yet another significant case challenging FDA's enforcement on First Amendment grounds. In Pacira v. FDA 15-cv-7055-RA, the plaintiff alleged that the FDA had declared truthful information to be false and punished the manufacturer for disseminating "false information." For a discussion of the dispute in Pacira see our prior post here. Procedurally similar to Amarin, Pacira was in the driver's seat because the FDA had little leverage to threaten Pacira into defeat.

While Pacira added nothing new to the festering constitutional hubbub in the Second Circuit created by Sorrell v IMS and then US v Caronia, Pacira boasted something more, unique and compelling facts. The First Amendment speech at issue for Pacira concerned "on-label information about use of a product for its FDA-approved indication" appeared to all on-lookers to be a sure win for Pacira. Apparently, the FDA agreed. On October 13, 2015 the FDA took an unusual step and rescinded the Warning Letter sent to Pacira and, at the insistence of Pacira, in the parties' Stipulation and Order of Dismissal filed on December 14, 2015, the FDA posted its letter to Pacira explaining the reasoning (here) for withdrawing the Warning Letter and putting a happy face on the terms of the Stipulation and Order resolving the litigation on December 15, 2015.

In the Settlement Agreement the parties address an apparent lack of decorum and define the "Regulatory Environment" wherein Pacira and FDA "Agree that, in future interactions, they will deal with each other in an open, forthright, and fair manner." Presumably, openness, forthrightness and fair dealing were in short supply in the parties dealings in this case and, if the result is any indication, Pacira seems to have gotten the best of FDA.

The Settlement Agreement is a complete capitulation and surrender by the FDA and bears none of the usual distain the FDA has shown for Due Process and First Amendment challenges. In the Settlement, FDA acknowledges it withdrew its Warning Letter, issued an agreed letter explaining why it withdrew its Warning Letter, agreed to issue a letter approving Pacira's Labeling Supplement, and approved agreed prescribing information, all of which gave Pacira everything it had on its wish list for Christmas.

It is too bad that the FDA relented so completely because Pacira v. FDA might have been a vehicle for the further development of important precedent building on US v. Caronia. Unlike its predecessor First Amendment cases, Pacira did not concede that the speech at issue was commercial speech. This is no minor technicality, because where the manufacturer does not concede that the speech at issue is commercial speech, the burden on the government to justify its restriction on speech is much greater.

Conclusion: The Speech Dilemma – What Is That Light at the End of the Tunnel?

The FDA's regulatory enforcement ship continues to sink as a result of the agency's ongoing refusal to recognize the significance of Due Process and the First Amendment in the context of FDA oversight of speech. Earlier in 2015 FDA suggested but never followed through on its utterances that it would hold public hearings and get the reasoned voice of industry and the public to fashion new guidance on what has become a public health imperative to provide more, not less, truthful scientific and medical information to the medical community and to the public concerning approved products. It is now imperative that FDA follow through with its commitment to take the First Amendment seriously.

Before applauding the demise of FDA's stranglehold on the dissemination of truthful scientific information too loudly, manufacturers would be well advised to recognize the freight train of tort claims approaching and heed the Amarin court's suggestion to "consult with the FDA before promoting off-label use." An FDA stamp of approval on a company's marketing efforts may be a lifeline to preserve a preemption challenge. In what may turn out to be a frequently quoted statement, the Amarin court highlighted the duty owed by manufacturers stating:

"Amarin bears the responsibility, going forward, of assuring that its communications to doctors regarding off-label use... remain truthful and non-misleading."

At the same time, industry might recognize the double edge the First Amendment sword presents and take reasonable steps to recommend how the FDA might balance commerce with constitutional considerations. With history as a guide, the work is far from done because tort claimants may pose a more formidable threat to manufacturers than the FDA. Only time will tell whether industry has won the battle only to lose the war.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Michael A. Walsh
Similar Articles
Relevancy Powered by MondaqAI
Fish & Richardson PC
Proskauer Rose LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Fish & Richardson PC
Proskauer Rose LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions